Immunocore Holdings plc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Immunocore Holdings plc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $249.43M | Feb 28, 2024 |
| FY2023 | Dec 31, 2022 | $174.36M | Feb 28, 2024 |
| FY2023 | Dec 31, 2021 | $36.48M | Feb 28, 2024 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $400.02M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $310.20M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $249.43M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $174.36M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $4.08M | Feb 28, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($35.51M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($51.09M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($55.29M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($52.54M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($180.03M) | Feb 28, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($45.35M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($70.46M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($59.65M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($51.71M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($174.59M) | Feb 28, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $274.87M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $222.15M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $163.55M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $101.92M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $100.25M | Feb 28, 2024 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $165.41M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $155.78M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $144.50M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $123.06M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $110.82M | Feb 28, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.71M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $26.06M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $2.94M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($49.21M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($143.11M) | Feb 28, 2024 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.34M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $5.17M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $5.43M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $2.20M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $1.39M | Feb 28, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.07B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.01B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $597.00M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $526.76M | Feb 28, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $686.24M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $648.79M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $228.16M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $187.86M | Feb 28, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $381.03M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $360.72M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $368.84M | Feb 25, 2026 |
| FY2025 | Dec 31, 2022 | $338.90M | Feb 25, 2026 |
| FY2024 | Dec 31, 2021 | $233.71M | Feb 26, 2025 |
| FY2023 | Dec 31, 2020 | $76.91M | Feb 28, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($831.28M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($795.76M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | ($744.67M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | ($689.39M) | Feb 28, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $467.71M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $455.73M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $442.63M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $402.47M | Feb 28, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | (4) | Feb 28, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | (4) | Feb 28, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 50.69M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 50.06M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | 49.73M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | 48.09M | Feb 28, 2024 |